Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
about
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myelomaThrombosis in multiple myelomaThalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.Thalidomide and immunomodulatory drugs in the treatment of cancer.Current treatment options for myeloma.A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.Thalidomide in multiple myeloma: past, present and future.New horizons in multiple myeloma therapy.An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myelomaPrevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.Review of thalidomide in the treatment of newly diagnosed multiple myeloma.Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma.Thalidomide-Related Eosinophilic Pneumonia: A case report and brief literature review.Role of thalidomide in previously untreated patients with multiple myeloma.Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma.Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.Safety and efficacy of primary thromboprophylaxis in cancer patients.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo.Evolving role of high dose stem cell therapy in multiple myeloma.Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism.
P2860
Q28194391-8DDCADF7-BD41-49AE-B13D-F302FCE0DB7BQ28219961-ADF366D9-DD76-4288-B2B5-F862C1831A65Q33364235-4EBDCB6D-FB37-47D5-BD7C-98E16CF2DF98Q33681168-1B041229-658E-4C74-9AE6-630E75FFB762Q36040871-BC06945F-6BAE-40B3-A289-74BBCCA44C35Q36163971-F1950D9C-2BCB-446D-9714-C85A7D55FA46Q36381565-8897AC36-259E-4F86-8990-0AB2C2EBFA75Q36616493-5116FB87-76E2-44E3-B237-36B46F4CBE18Q36636660-D1FD03B4-A83B-45DB-A134-C531F850642CQ36695180-51E220C7-8557-498A-A7E8-D3D4AC59A98DQ37038414-DABF282C-54C5-4100-A2B8-C22085605955Q37160347-E3DA11A0-B096-4A31-BDAF-F4F870DEDD80Q37230257-BD82B6A6-96CD-4F96-A971-241C52876ED5Q37263330-9D02E4DD-6F1E-44A3-8043-FC8E40AB803AQ37300004-A45363AD-FDD3-43D7-AF4F-9D618B1F14F4Q37546023-3AC37128-1403-4CEA-B9F7-714205AEEEA4Q37831402-511E6116-E683-42F5-B404-B104939E9150Q38065298-02BC3CB4-9D1F-4CA2-804D-FAB8E4F0FCD2Q38555091-0308C674-1302-44BF-82F1-FF983BB438ECQ38826115-ABF34C5C-439E-45DC-B238-C269E9D3E1B4Q39138108-EF82C978-827A-406F-8ADA-84C95F81CDADQ41825014-C7DD5090-332A-4A61-A062-DA01572E1AB1Q42287525-F2A4628E-C728-42EA-AD9E-A52BD0DC7451Q44619463-00791C3C-AFE1-4827-B667-5D6329E4BF6DQ45095148-7986C551-4510-42A5-B425-E33518757BD7Q53584702-A5EFA262-1CBE-4E96-BEA9-CEC2E850FD04
P2860
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Primary treatment of multiple ...... a phase II multicenter study.
@ast
Primary treatment of multiple ...... a phase II multicenter study.
@en
type
label
Primary treatment of multiple ...... a phase II multicenter study.
@ast
Primary treatment of multiple ...... a phase II multicenter study.
@en
prefLabel
Primary treatment of multiple ...... a phase II multicenter study.
@ast
Primary treatment of multiple ...... a phase II multicenter study.
@en
P2093
P921
P356
P1433
P1476
Primary treatment of multiple ...... a phase II multicenter study.
@en
P2093
A Anagnostopoulos
A Maniatis
Ch Mitsouli
E Hatzicharissi
Greek Myeloma Study Group
J Korantzis
M Papaioannou
M Tzilianos
P Panagiotidis
P304
P356
10.1093/ANNONC/MDH026
P577
2004-01-01T00:00:00Z